Evidence map›Paper›PMID 31243630›Full record

ArticleGlycoconjugate journal2019

Stage-specific embryonic antigen-4 is a histological marker reflecting the malignant behavior of prostate cancer.

Yuichiro Nakamura, Yasuyoshi Miyata, Tomohiro Matsuo, Yohei Shida, Tomoaki Hakariya, Kojiro Ohba, Takenobu Taima, Akihiro Ito, Tetsuji Suda, Sen-Itiroh Hakomori and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Glycoconjugate journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Increased expression of SSEA-4 on TKI-resistant non-small cell lung cancer with EGFR-T790M mutation.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. American journal of cancer research · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Yuichiro NakamuraDepartment of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Yasuyoshi MiyataDepartment of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. yasu-myt@nagasaki-u.ac.jp.
Tomohiro MatsuoDepartment of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Yohei ShidaDepartment of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Tomoaki HakariyaDepartment of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Kojiro OhbaDepartment of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Takenobu TaimaDepartment of Urology, Tohoku University Graduate School of Medicine, Miyagi, 980-8574, Japan.
Akihiro ItoDepartment of Urology, Tohoku University Graduate School of Medicine, Miyagi, 980-8574, Japan.
Tetsuji SudaDepartment of Urology, University of the Ryukyus, Okinawa, 903-0215, Japan.
Sen-Itiroh HakomoriDepartments of Pathobiology and Global Health, University of Washington, Seattle, WA, 98112, USA.
Seiichi SaitoDepartment of Urology, University of the Ryukyus, Okinawa, 903-0215, Japan.
Hideki SakaiDepartment of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Nagasaki University · JPTohoku University · JPUniversity of the Ryukyus · JPUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stage-specific embryonic antigen-4 (SSEA-4), a specific marker for pluripotent stem cells, plays an important role in the malignant behavior of several cancers. Here, SSEA-4 expression was evaluated by immunohistochemistry using monoclonal antibody RM1 specific to SSEA-4 in 181 and 117 prostate cancer (PC) specimens obtained by biopsy and radical prostatectomy (RP), respectively. The relationships between SSEA-4 expression in cancer cells or the presence of SSEA-4-positive tumor-infiltrating immune cells (TICs) and clinicopathological parameters were analyzed. SSEA-4 expression in cancer cells was significantly associated with Gleason score, local progression, and lymph node and distant metastasis. In RP specimens, high SSEA-4 expression in cancer cells and the presence of SSEA-4-positive TICs were significant predictors of pT3, i.e., invasion and worse biochemical recurrence (BCR) after RP, respectively, in univariate analysis. In contrast, combination of high SSEA-4 expression in cancer cells and the presence of SSEA-4-positive TICs was an independent predictor for pT3 and BCR in multivariate analysis. Biologically this combination was also independently associated with suppression of apoptosis. Thus, the co-expression of SSEA-4 in cancer cells and TICs may have crucial roles in the malignant aggressiveness and prognosis of PC. Invasive potential and suppression of apoptosis may be linked to SSEA-4 expression.

Indexed as

AgedApoptosisBiomarkers, TumorBiopsyGlycosphingolipidsHumansLymphatic MetastasisLymph NodesLymphocytes, Tumor-InfiltratingMaleMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingPrognosisBiomarkers, TumorGlycosphingolipidsstage-specific embryonic antigen-4Stage-Specific Embryonic AntigensApoptosis · prostate cancerBiochemical recurrenceSSEA-4Tumor-infiltrating immune cells

Identifiers

PMID31243630
PMCPMC6744380
OpenAlexW2954566924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.